Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
7 matches for “Vial”; 5 quoted, at least 25 words apart.
…respectively at the end of Q1. We also launched higher dose Zepbound vials adding two additional doses for patients to access Zepbound through the self-pay…
…in the marketplace. We will continue those efforts across the PBMs, Medicaid and North America and of course our self-pay effort with vials as well.
…Wegovy cash pay pens. So my question is whether Zepbound cash pay vials are available in the U.S. in any pharmacy chain today? And given…
…there. But Patrik, do you want to take the question on the vials, the cash pay distribution and if we would ever think of other…
…change that we announced earlier this year and the launch of high-dose vials has significantly contributed to an even further acceleration of the market growth.…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP